Amylyx's Unlikely Comeback Started With a Sugar Crash
Amylyx was left for dead after its ALS drug imploded. Two years later, a $35 million acquisition just delivered Phase 3 data so strong it could create the first approved treatment for a post-surgical complication nobody's been able to fix.
The Company Everyone Counted Out Just Dropped Blockbuster Data
Two years ago, Amylyx Pharmaceuticals was the biotech equivalent of a team that just got relegated. Its ALS drug Relyvrio flopped in a confirmatory Phase 3 trial, got pulled from the U.S. and Canadian markets, and left behind a company that needed to reinvent itself fast. Layoffs followed. So did a lot of skepticism.
On Monday, Amylyx reminded everyone why second acts exist in biotech.
The company reported that avexitide, a drug it picked up for roughly $35 million from Eiger BioPharmaceuticals in 2024, cut blood sugar crashes by 59% in patients who developed a nasty complication after weight-loss surgery. The p-value (a measure of statistical confidence; the lower, the better) came in at less than 0.001. For context, anything below 0.05 is generally considered meaningful. This result wasn't just statistically significant; it was a blowout.
What Happens When Your Stomach Gets Rerouted
To understand why this matters, you need to understand the problem avexitide is trying to solve.
Bariatric surgery, particularly Roux-en-Y gastric bypass, reroutes how food travels through your digestive system. It's effective for weight loss. But for a meaningful chunk of patients, the rerouting creates an unintended side effect: their bodies start overreacting to meals.
Think of it like a thermostat that's been rewired incorrectly. Instead of keeping the temperature steady, it cranks the AC way too hard every time things warm up slightly. In this case, the "AC" is insulin, and the result is blood sugar that plummets to dangerously low levels after eating. That condition is called post-bariatric hypoglycemia (PBH), and it can cause dizziness, confusion, fainting, and even seizures.
How common is it? That depends on who you ask and how you measure it. Studies using continuous glucose monitors have found hypoglycemia in more than half of post-surgical patients. A more conservative estimate pegs clinically significant PBH at roughly 160,000 people in the U.S. Some models put the number even higher, above 450,000.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The kicker: there are zero approved drugs for this condition. Patients currently manage it with dietary changes and a grab bag of off-label medications like acarbose and diazoxide. If those don't work, the last resort is literally reversing the surgery.
Fighting GLP-1 Instead of Boosting It
If you've heard of GLP-1, it's probably because of Ozempic, Wegovy, and the weight-loss revolution. Those drugs are GLP-1 agonists, meaning they mimic or amplify GLP-1's effects to help people feel full and control blood sugar.
Avexitide does the opposite. It's a GLP-1 receptor antagonist, which means it blocks GLP-1 signaling. Why would anyone want to do that?
Because after gastric bypass, many patients produce an exaggerated GLP-1 response every time they eat. That flood of GLP-1 tells the pancreas to dump out way too much insulin, which is what sends blood sugar crashing. Avexitide essentially puts a bouncer at the door of the GLP-1 receptor, preventing that overblown signal from triggering an insulin avalanche.
It's a clever inversion of one of the hottest drug classes in medicine. While every other company is racing to enhance GLP-1 activity, Amylyx is betting big on dialing it down for the patients who have too much of a good thing.
The LUCIDITY Trial: Clean, Convincing, Complete
The Phase 3 trial, called LUCIDITY, enrolled 78 patients with PBH after Roux-en-Y gastric bypass. It was randomized, double-blind, and placebo-controlled across multiple centers. Patients were tracked for 16 weeks using continuous glucose monitors, fingerstick blood sugar readings, and electronic diaries.
The primary endpoint was straightforward: reduce the rate of Level 2 and Level 3 hypoglycemic events. Level 2 means blood sugar drops low enough to cause symptoms. Level 3 means it drops so far the patient needs someone else's help to recover (think seizures or loss of consciousness).
Avexitide met the primary endpoint, cutting those episodes by 59% compared to placebo. Every secondary endpoint fell into line too, including reductions measured by both continuous glucose monitoring and traditional fingerstick methods. On the safety front, adverse events were mostly mild to moderate.
A $35 Million Bet That's Looking Pretty Smart
Rewind to 2024. Amylyx had just watched Relyvrio crater. The company slashed its workforce, cut external spending, and went shopping for a new lead asset. It found avexitide sitting at Eiger BioPharmaceuticals with promising Phase 2 data and no clear path to Phase 3 under Eiger's roof.
Amylyx paid about $35.1 million for the asset, moved it into Phase 3 by early 2025, and completed enrollment in the LUCIDITY trial by March 2026. The whole timeline from acquisition to positive pivotal data took roughly two years. In biotech, that's practically speed-dating compared to the decade-long courtships most drug programs require.
If the company files for FDA approval and gets it (commercialization has been guided for 2027), avexitide would be the first approved treatment for post-bariatric hypoglycemia. First-in-class, first-to-market, in a space with zero competition from approved drugs.
The Competition (or Lack Thereof)
Avexitide isn't completely alone in the PBH pipeline, but it's far ahead of the pack. A handful of other candidates are floating around in earlier stages: mizagliflozin (an SGLT1 inhibitor in Phase 2), pasireotide (a somatostatin analog in Phase 2), and a few other early-stage programs like imapextide and CFTX-2034.
None of them have Phase 3 data. Avexitide's head start is significant, and the LUCIDITY results give it a clear regulatory path that competitors will need years to match.
Amylyx also has AMX0318, a long-acting GLP-1 receptor antagonist in its own pipeline, which could eventually offer a next-generation option. Beyond PBH, the company is developing AMX0035 for Wolfram syndrome and progressive supranuclear palsy, plus AMX0114 for ALS.
The Bigger Picture
Bariatric surgery volumes have been climbing for years, and GLP-1 agonists are creating a new wave of awareness around metabolic health. Ironically, the same drug class generating headlines for weight loss is part of the biological problem avexitide is designed to fix. As more people undergo gastric bypass, the population of PBH patients will grow.
Amylyx's story is a reminder that biotech companies are not their first drug. The Relyvrio failure was brutal, public, and humbling. But the speed and discipline with which Amylyx pivoted to avexitide, acquired it cheaply, ran a clean trial, and delivered a statistically resounding result is genuinely impressive.
The stock market will ultimately decide whether this is a true comeback story or a niche win in a small market. But for the tens of thousands of patients who can't eat a meal without fearing they'll pass out, Monday's data might be the most important thing that's happened in their disease in a very long time.
Deals & M&A
4 min read
LEO Pharma Just Paid $435M for a Drug That Isn't Approved Yet
LEO Pharma is spending up to $435 million on a drug that isn't even approved yet. But dersimelagon could be the first real treatment for a brutal sun allergy, and LEO's rare-dermatology shopping spree is starting to look like a masterplan.
